European Academy of Allergy and Clinical Immunology

ASLAN Pharmaceuticals to Co-Host KOL Panel Discussion Today on Changes in the Clinical Trial and Treatment Landscape for Atopic Dermatitis

Retrieved on: 
Tuesday, October 24, 2023
Standard of care, AD, George Washington University School of Medicine & Health Sciences, Clinical trial, Outline of health sciences, Internet, Physician, Congress, MD, Research, Contract research organization, Dupilumab, Drug development, Addiction severity index, European Academy of Allergy and Clinical Immunology, Disease, Webcast, ASLN, EASI, UCLA, Atopic dermatitis, Patient, Pharmaceutical industry, Dermatology, Venereology

During the event, ASLAN will present additional analyses of the TREK-AD patient population building on data recently published at the 32nd European Academy of Dermatology and Venereology (EADV) Congress.

Key Points: 
  • During the event, ASLAN will present additional analyses of the TREK-AD patient population building on data recently published at the 32nd European Academy of Dermatology and Venereology (EADV) Congress.
  • ASLAN will also present new insights on the AD treatment landscape based on a recently conducted survey of physicians and AD patients in the US.
  • “We are pleased to be contributing to today’s discussion that aims to spark a dialogue on the changing AD patient profile that presents in clinical studies.
  • Register here to attend the webcast or watch the replay of the event, which will be available for 180 days.

UNION therapeutics to present at 7th Annual Dermatology Drug Development Summit in Boston

Retrieved on: 
Wednesday, October 25, 2023
Drug development, HS, Infection, Therapy, Congress, IR, OSIRIS, Communication, A/S, European Academy of Allergy and Clinical Immunology, Hidradenitis suppurativa, Steven Myers (CEO), UNION, Pharmaceutical industry, Dermatology

HELLERUP, Denmark, Oct. 25, 2023 /PRNewswire/ -- UNION therapeutics A/S (UNION), a privately held, clinical stage, pharmaceutical development company focused on immunology and infectious disease, today announced that Dr. Kim D. Kjøller, CEO of UNION therapeutics will present at the seminar on clinical trials at the 7th Annual Dermatology Drug Development Summit on October 31 - November 2, 2023, in Boston, US.

Key Points: 
  • HELLERUP, Denmark, Oct. 25, 2023 /PRNewswire/ -- UNION therapeutics A/S (UNION), a privately held, clinical stage, pharmaceutical development company focused on immunology and infectious disease, today announced that Dr. Kim D. Kjøller, CEO of UNION therapeutics will present at the seminar on clinical trials at the 7th Annual Dermatology Drug Development Summit on October 31 - November 2, 2023, in Boston, US.
  • Dr. Kjøller will discuss recent challenges and progress in assessing efficacy in clinical trials of hidradenitis suppurativa (HS) and how novel endpoints may improve the approach.
  • To perspectivize the discussion, data from the OSIRIS, proof-of-concept study of oral orismilast in HS presented at the European Academy of Dermatology and Venerology (EADV) Congress 2023 will be presented.
  • Sarah Toft-Jørgensen, Director of Communications and IR, UNION therapeutics A/S

Press Release: Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis

Retrieved on: 
Friday, October 13, 2023
Congress, Conjunctivitis, Psoriasis Area and Severity Index, Atopic dermatitis, European Academy of Allergy and Clinical Immunology, Journal of the European Academy of Dermatology and Venereology, Patient, Disease, IGA, Vaccine, Dermatology, Venereology, EASI

The Phase 3 program for amlitelimab in atopic dermatitis is on track to start in the first half of 2024.

Key Points: 
  • The Phase 3 program for amlitelimab in atopic dermatitis is on track to start in the first half of 2024.
  • Global Head of Research & Development, Sanofi
    “The data presented at EADV provide more detailed insight into amlitelimab’s potential as a best-in-class therapy for people with atopic dermatitis.
  • TEAEs more commonly observed with amlitelimab compared to placebo included nasopharyngitis (11.0% amlitelimab, 9.0% placebo), COVID-19 (7.7% amlitelimab, 6.4% placebo) and headache (6.1% amlitelimab, 2.6% placebo).
  • Worsening of atopic dermatitis was more commonly observed with placebo compared to amlitelimab (38.5% placebo, 17.1% amlitelimab).

Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress

Retrieved on: 
Wednesday, October 11, 2023
Congress, European Academy of Allergy and Clinical Immunology, BTLA, Therapy, Atopic dermatitis, CEST, SAN, Vaccine, Dermatology

SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced two upcoming presentations at the 32nd European Academy of Dermatology and Venerology (EADV) Congress in Berlin, Germany, Oct. 11-14, 2023.

Key Points: 
  • SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced two upcoming presentations at the 32nd European Academy of Dermatology and Venerology (EADV) Congress in Berlin, Germany, Oct. 11-14, 2023.
  • The oral presentation will focus on ANB032’s previously reported healthy volunteer Phase 1 data and the trial-in-progress poster presentation will focus on ANB032’s Phase 2b study in moderate to severe atopic dermatitis.
  • The company’s planned activities are listed below and the full preliminary program is available online on the EADV website.
  • ANB032, a novel BTLA agonist monoclonal antibody, inhibits T cell proliferation, reduces inflammatory cytokines, and down modulates BTLA expression on circulating T and B cells: Results from a first-in-human Phase 1 study (abstract #5603)
    Session Date and Time – Friday, Oct. 13, 2023 from 8:30am – 10:40am CEST

Trevi Therapeutics Announces Results from Phase 2b/3 PRISM Open-Label Extension Study of Haduvio™ in Prurigo Nodularis

Retrieved on: 
Friday, October 13, 2023
Congress, European Academy of Allergy and Clinical Immunology, OLE, Vomiting, BID, Dermatology, Nalbuphine, IPF, Prurigo nodularis, Somnolence, Nausea, Idiopathic pulmonary fibrosis, FDA, Therapy, Chronic cough, Itch, Fatigue, Dizziness, PRISM, Patient, Pharmaceutical industry, Safety

NEW HAVEN, Conn., Oct. 13, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for difficult to treat patients with chronic cough in idiopathic pulmonary fibrosis (IPF), other chronic cough indications and prurigo nodularis, today announced the 52-week results from its phase 2b/3 PRISM open-label extension (OLE) study of Haduvio for the treatment of prurigo nodularis. The data was presented by Professor Elke Weisshaar on October 13th at the European Academy of Dermatology & Venereology (EADV) Congress 2023 in Berlin, Germany. The slides from the presentation will be available for 30 days on the Company's website.  

Key Points: 
  • The slides from the presentation will be available for 30 days on the Company's website .
  • "The long-term data also supports the continued effectiveness of Haduvio in reducing itch over 52 weeks for the participants who remained in the study.
  • We are preparing for an end of phase 2 meeting with the FDA to discuss next steps in development for this program."
  • The phase 2b/3 PRISM (Pruritus Relief through Itch-Scratch Modulation) trial was a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of nalbuphine ER in prurigo nodularis.

Novel classification of allergic disorders published by the European Academy of Allergy and Clinical Immunology: SIAF

Retrieved on: 
Tuesday, October 10, 2023
Medicine, European Academy of Allergy and Clinical Immunology, EAACI, Research, Health, Classification, Patient, Education, Nanotechnology, Wrocław Medical University, Tissue, Swiss Institute of Allergy and Asthma Research, Skin, Human, Allergy, Infection, Organ dysfunction, Medical device, Vaccine

DAVOS, Switzerland, Oct. 10, 2023 /PRNewswire/ -- The revision of the current allergic disease nomenclature based on symptoms and organ dysfunction has been long-awaited at the time of modern patient-tailored treatments and precision medicine. The new classification is based on disease mechanisms, thus facilitating targeted and personalised disease management.

Key Points: 
  • The new classification is based on disease mechanisms, thus facilitating targeted and personalised disease management.
  • The world's key opinion leaders gathered around the initiative of the European Academy of Allergy and Clinical Immunology (EAACI) to present a new classification of allergic disorders based on the mechanisms of diseases.
  • Published online today in Allergy, the position paper reveals the new way allergic diseases are perceived.
  • We expect the new classification to  profoundly change the healthcare professionals' approach to managing allergic diseases since it provides key solutions to a personalised approach.

Novel classification of allergic disorders published by the European Academy of Allergy and Clinical Immunology: SIAF

Retrieved on: 
Tuesday, October 10, 2023
Medicine, European Academy of Allergy and Clinical Immunology, EAACI, Research, Health, Classification, Patient, Education, Nanotechnology, Wrocław Medical University, Tissue, Swiss Institute of Allergy and Asthma Research, Skin, Human, Allergy, Infection, Organ dysfunction, Medical device, Vaccine

DAVOS, Switzerland, Oct. 10, 2023 /PRNewswire/ -- The revision of the current allergic disease nomenclature based on symptoms and organ dysfunction has been long-awaited at the time of modern patient-tailored treatments and precision medicine. The new classification is based on disease mechanisms, thus facilitating targeted and personalised disease management.

Key Points: 
  • The new classification is based on disease mechanisms, thus facilitating targeted and personalised disease management.
  • The world's key opinion leaders gathered around the initiative of the European Academy of Allergy and Clinical Immunology (EAACI) to present a new classification of allergic disorders based on the mechanisms of diseases.
  • Published online today in Allergy, the position paper reveals the new way allergic diseases are perceived.
  • We expect the new classification to  profoundly change the healthcare professionals' approach to managing allergic diseases since it provides key solutions to a personalised approach.

Janssen Highlights Latest Research for TREMFYA® (guselkumab) and Investigational Targeted Oral Peptide JNJ-2113 in Moderate to Severe Plaque Psoriasis at the European Academy of Dermatology and Venereology (EADV) Congress

Retrieved on: 
Monday, October 9, 2023
Congress, Red, Quality of life, PASI, European Academy of Allergy and Clinical Immunology, Treatment, Oral, Abstract, SPRING, Janssen, Health and Quality of Life Outcomes, Johnson & Johnson, Janssen Pharmaceuticals, Disease, Real Life, HOUSE, Psoriasis Area and Severity Index, Journal of the European Academy of Dermatology and Venereology, Macrophage, Plaque, Overalls, Safety, Science, Political moderate, Pharmaceutical industry, Medical imaging, Vaccine, Psoriasis, Dermatology, Venereology, Libido, PSO, Patient

SPRING HOUSE, Pa., Oct. 9, 2023 /PRNewswire/ -- Janssen Pharmaceuticals, Inc., a Johnson & Johnson company, today announced that 30 company-sponsored presentations will be featured at the European Academy of Dermatology and Venereology (EADV) Congress taking place in Berlin, Germany from October 11-14, 2023. Janssen will present new data on the underlying science of the treatment of psoriasis (PsO), including results from the Phase 3b GUIDE trial highlighting early intervention with TREMFYA® (guselkumab) (Abstract #FC08.5)1 and systemic pharmacodynamica response data for JNJ-2113 from the Phase 2 FRONTIER 1 trial (Abstract #FC08.2).2

Key Points: 
  • "Patients are waiting for a new option with the goal of helping manage their plaque psoriasis symptoms, which could potentially transform the treatment paradigm.
  • The data from these presentations add to the comprehensive body of scientific evidence for our investigational and established therapies, potentially offering people living with moderate to severe plaque psoriasis much-needed relief from their symptoms."
  • A selection of Janssen-sponsored abstracts being featured at EADV is provided below.
  • Systemic pharmacodynamics is the study of the biochemical and physiologic effects of drugs in the body.

Stigmatisation a major impact of skin diseases across Europe, reveals JEADV study

Retrieved on: 
Sunday, October 8, 2023
European Academy of Allergy and Clinical Immunology, STD, Research, Advocacy, Prevalence, Burden, Skin, Atopic dermatitis, Stigmata, Psoriasis, Disease, Skin condition, Mental health, Journal of the European Academy of Dermatology and Venereology, Journal, Policy, Vertically transmitted infection, Hives, Life, Hair, Acne, Patient, Quality of life, Nursing, Dermatology, Venereology

Published today in the Journal of the European Academy of Dermatology and Venereology (JEADV), the diseases examined in the study included acne, atopic dermatitis, alopecia, psoriasis and sexually transmitted diseases (STDs).

Key Points: 
  • Published today in the Journal of the European Academy of Dermatology and Venereology (JEADV), the diseases examined in the study included acne, atopic dermatitis, alopecia, psoriasis and sexually transmitted diseases (STDs).
  • 88% patients with skin disease considered their disease to be embarrassing in their personal life, with 83% reporting the same in their working life.
  • The prevalence of skin diseases is likely to be significantly higher than this, as 40% of skin cancers and STD diagnoses remain unrecognised on first consultation.
  • Despite their high prevalence and psychological and physical impact, skin diseases receive limited policy, research and funding attention.

Apogee Announces Two Abstracts Accepted for Presentation at the 2023 European Academy of Dermatology and Venereology (EADV) Congress

Retrieved on: 
Wednesday, September 27, 2023
Paragon, Abstract, Asthma, Half-life, I&I, Atopic dermatitis, Chronic obstructive pulmonary disease, Congress, European Academy of Allergy and Clinical Immunology, Patient, Immunoglobulin G, Primate, SAN, AD, Therapy, Pharmaceutical industry, Dermatology, Venereology

SAN FRANCISCO, CA and WALTHAM, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease and other inflammatory and immunology (I&I) indications, today announced two abstracts co-written with Apogee’s research partner, Paragon Therapeutics, Inc., highlighting the company’s lead product candidate, APG777, a fully optimized and half-life extended antibody targeting IL-13 for the treatment of AD, have been accepted as e-posters at the upcoming 2023 European Academy of Dermatology and Venereology (EADV) Congress, held October 11-14, 2023, in Berlin, Germany and virtually.

Key Points: 
  • SAN FRANCISCO, CA and WALTHAM, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease and other inflammatory and immunology (I&I) indications, today announced two abstracts co-written with Apogee’s research partner, Paragon Therapeutics, Inc., highlighting the company’s lead product candidate, APG777, a fully optimized and half-life extended antibody targeting IL-13 for the treatment of AD, have been accepted as e-posters at the upcoming 2023 European Academy of Dermatology and Venereology (EADV) Congress, held October 11-14, 2023, in Berlin, Germany and virtually.
  • “We are excited to share our preclinical findings on APG777 during the EADV Congress, which underscore the potential advantages of APG777 over current therapeutic agents targeting IL-13, including half-life,” said Carl Dambkowski, M.D., Chief Medical Officer of Apogee Therapeutics.
  • “With currently available biologic treatments dosed every 2 or 4 weeks for patients with atopic dermatitis, the potential significant reduction in injection burden to every two- or three-month dosing that we believe APG777 will offer could be paradigm shifting for atopic dermatitis.
  • We are eagerly awaiting our Phase 1 clinical trial results next year and are enthusiastic about exploring its potential in addressing a spectrum of I&I conditions beyond AD, including asthma and more.”
    The e-posters will be available for viewing during the EADV Congress beginning on Wednesday, October 11, 2023, and details are as follows:
    Title: APG777, a high-affinity humanized IgG1 mAb targeting IL-13, demonstrates prolonged half-life in non-human primates